Jane Hughes
Chief Tech/Sci/R&D Officer chez GYROSCOPE THERAPEUTICS HOLDINGS PLC
Profil
Jane Hughes is currently the Chief Scientific Officer at Gyroscope Therapeutics Holdings Plc since 2019.
Prior to this, she worked as the Senior Director-Integrated Drug Discovery at Charles River Laboratories, Inc. from 2017 to 2018 and as the Director-Discovery Medicine & Immuno Inflammation at GSK Plc from 2014 to 2017.
She obtained a doctorate degree from Keele University.
Postes actifs de Jane Hughes
| Sociétés | Poste | Début |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 01/10/2019 |
Anciens postes connus de Jane Hughes
| Sociétés | Poste | Fin |
|---|---|---|
Charles River Laboratories, Inc.
 Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA. | Corporate Officer/Principal | 01/11/2018 |
| GSK PLC | Corporate Officer/Principal | 01/06/2017 |
Formation de Jane Hughes
| Keele University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Charles River Laboratories, Inc.
Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA. | Commercial Services |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
